Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4265-4276

  Cheng, Mingrong ^a   Gao, Xiaoyan ^a   Wang, Yong ^b   Chen, Houxiang ^c   He, Bing ^d   Li, Yingchun ^a   Han, Jiang ^a   Zhang, Zhiping ^a  

^a Pudong New Area Zhoupu Hospital   (China)

^b WUHAN UNIVERSITY OF TECHNOLOGY   (China)

^c Zhejiang Huafon Fiber Research Institute   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; Chemotherapy; Liver cancer; Targeted therapy

Indexed keywords

CHITOSAN; FLUOROURACIL; GLYCYRRHETINIC ACID; LACTIC ACID; LACTOBIONIC ACID; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMICAL COMPOSITION; CHEMICAL PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; GENTLE RELEASE FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER TRANSPLANTATION; MOUSE; NONHUMAN; PARTICLE SIZE; POLYDISPERSITY INDEX; RAT; SECOND BURST RELEASE FORMULATION; SLOW RELEASE FORMULATION; SMALL BURST RELEASE FORMULATION; STEADY RELEASE FORMULATION; ZETA POTENTIAL;

5-FLUOROURACIL; CHEMOTHERAPY; LIVER CANCER; TARGETED THERAPY;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NANOPARTICLES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887324032     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S52877     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-156.
2. Chen WQ, Zheng RS, Zhang SW. Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 2013;32(4):162-169.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283-298.
4. Sun X, Wu F, Lu W, Zhang ZR. Sustained-release hydroxycamptothecin polybutylcyanoacrylate nanoparticles as a liver targeting drug delivery system. Pharmazie. 2004;59(10):791-794.
5. Zhang X, Zhang X, Yu P, Han Y, Li Y, Li C. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system. J Pharm Sci. 2013;102(1):145-153.
6. Wang Q, Zhang L, Hu W, et al. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine. 2010;6(2):371-381.
7. Yang W, Mou T, Guo W, et al. Fluorine-18 labeled galactosylated chitosan for asialoglycoprotein-receptor-mediated hepatocyte imaging. Bioorg Med Chem Lett. 2010;20(16):4840-4844.
8. Feng ZQ, Chu X, Huang NP, et al. The effect of nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte aggregates and the maintenance of liver function. Biomaterials. 2009;30(14):2753-2763.
9. He ZY, Zheng X, Wu XH, et al. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int J Pharm. 2010;397(1-2):147-154.
10. Huang W, Wang W, Wang P, et al. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy. Acta Biomater. 2010;6(10):3927-3935.
11. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials. 2010;31(17):4748-4756.
12. Kakimoto S, Moriyama T, Tanabe T, Shinkai S, Nagasaki T. Dual-ligand effect of transferrin and transforming growth factor alpha on polyethyleneimine-mediated gene delivery. J Control Release. 2007;120(3):242-249.
13. Chen H, Li M, Wan T, et al. Design and synthesis of dual-ligand modified chitosan as a liver targeting vector. J Mater Sci Mater Med. 2012;23(2):431-441.
14. Toriumi F, Kubota T, Saikawa Y, et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 2004;24(4):2455-2463.
15. Johnson KR, Wang L, Miller MC, Willingham MC, Fan W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res. 1997;3(10):1739-1745.
16. Fang JY, Liu PF, Huang CM. Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr Drug Metab. 2008;9(7):592-597.
17. Chen Y, Wang X, Yan Z, Wang J, Luo J, Liu Q. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. Onkologie. 2012;35(9):480-484.
18. Takahashi Y, Yamashita K, Endo Y, Sasaki T, Mai M. Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system. Surg Today. 2004;34(10):855-859.
19. Oh IH, Min HS, Li L, et al. Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials. 2013;34(27):6454-6463.
20. Cheng M, He B, Wan T, et al. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One. 2012;7(10):e47115.
21. Giannì M, Koken MH, Chelbi-Alix MK, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 1998;91(11):4300-4310.
22. Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov Today. 2004;9(5):219-228.
23. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-4612.
24. Ballet F. Hepatic circulation: potential for therapeutic intervention. Pharmacol Ther. 1990;47(2):281-328.
25. Snow K, Judd W. Characterisation of adriamycin-and amsacrine-resistant human leukaemic T cell lines. Br J Cancer. 1991;63(1): 17-28.
26. Kuo MT, Bao JJ, Curley SA, Ikeguchi M, Johnston DA, Ishikawa T. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res. 1996;56(16):3642-3644.
27. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002;1587(2-3):164-173.
28. Violette S, Poulain L, Dussaulx E, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer. 2002;98(4):498-504.